ArticleJournal of translational medicine2026
Urinary ANGPTL3: a novel noninvasive biomarker for podocyte injury in pediatric glomerular diseases.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPodocyte injury constitutes the pathological basis of various glomerular diseases; however noninvasive tools for assessing podocyte injury remain limited. Angiopoietin-like protein 3 (ANGPTL3) has been shown to be pathologically elevated in glomerular diseases and is associated with podocyte injury. This study aimed to evaluate the clinical utility of the urinary ANGPTL3-to-creatinine ratio (ANGPTL3/Cre) as a noninvasive biomarker for assessing podocyte injury in children with glomerular diseases.
methodsRenal ANGPTL3 expression was first examined in tissue samples from pediatric patients with podocyte injury (n = 25) and controls (n = 5), and its associations with established histological markers of podocyte injury and urinary ANGPTL3 levels were analyzed. Subsequently, pediatric patients aged 1-18 years with glomerular diseases complicated with podocyte injury and healthy controls were enrolled and divided into a test set (n = 346) and a validation set (n = 150). ANGPTL3 levels in serum and urine were measured. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curves. Associations with podocyte injury and improvements in risk stratification were assessed using logistic regression and reclassification improvement (NRI/IDI) analyses, respectively.
resultsRenal ANGPTL3 expression correlated negatively with the podocyte injury markers P57Kip2 (r = -0.55, P = 0.002) and Synaptopodin (r = -0.37, P = 0.04), while correlating positively with urinary ANGPTL3/Cre (r = 0.64, P < 0.001). Urinary ANGPTL3/Cre was significantly elevated in patients with podocyte injury and served as an independent risk factor for this condition (OR = 7.66, 95% CI: 2.27-25.84, P = 0.001). It demonstrated superior diagnostic performance (area under the curve, AUC = 0.90 in both sets) compared to serum ANGPTL3 or traditional biomarkers for podocyte injury. When combined with clinical variables, the AUC improved to 0.95 (95% CI: 0.93-0.97) with enhanced risk reclassification for podocyte injury. High diagnostic efficacy (AUC = 0.88/0.86) was maintained even in patients with normal protein excretion after clinical treatment.
conclusionUrinary ANGPTL3/Cre is a reliable, noninvasive biomarker for podocyte injury in pediatric glomerular diseases. Notably, it may have potential value in identifying subclinical podocyte injury in patients with normal protein excretion, thereby supporting its robust potential for longitudinal monitoring and risk stratification in this patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.